Association of hyperuricemia combined with sarcopenia on ASCVD risk.
Atherosclerotic cardiovascular disease
Hyperuricemia
Insulin resistance
Sarcopenia
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
27 06 2023
27 06 2023
Historique:
received:
09
11
2022
accepted:
07
06
2023
medline:
29
6
2023
pubmed:
28
6
2023
entrez:
27
6
2023
Statut:
epublish
Résumé
Hyperuricemia and sarcopenia are both strongly linked to an increased risk of atherosclerotic cardiovascular disease (ASCVD), and this study was designed to look into the interactive effects of hyperuricemia on ASCVD risk. This study collected information from patients (N = 2647) who underwent health check-ups at the Health Care Building of Wuhan Union Hospital between January 2019 and December 2020. Skeletal muscle mass was measured using bioelectrical impedance methods. The Asian Working Group on Sarcopenia diagnostic criteria were used to classify patients with sarcopenia. ASCVD risk was calculated using the Framingham Heart Study, and ASCVD risk ≥ 20% was considered high risk ASCVD. IBM SPSS 25.0 and GraphPad prism 8.0 software were used for data analysis and graphing. The prevalence of hyperuricemia and sarcopenia was 23.57% and 15.34%, respectively. The occurrence of cardiovascular risk factors such as obesity, hypertension, diabetes mellitus, chronic kidney disease, and low HDL-Cemia was significantly higher in subjects with hyperuricemia combined with sarcopenia (OR = 1.734, 3.064, 1.61, 8.77 and 1.691 respectively, p < 0.05); Hyperuricemia and high-risk ASCVD were independently associated (OR = 1.355, 95% CI = 1.000-1.838, p = 0.04). Although there was no significant association between sarcopenia and high-risk ASCVD after controlling for confounders (OR = 1.274, 95% CI = 0.828-1.959, p = 0.271), sarcopenia combined with hyperuricemia significantly increased high-risk ASCVD (OR = 3.229, 95% CI 1.544-6.751, p = 0.002). Hyperuricemia is independently associated with high-risk ASCVD; Sarcopenia and high-risk ASCVD did not show an independent relationship, but there was a synergistic effect of the two on ASCVD risk, which may imply that managing both hyperuricemia and sarcopenia may have a greater cardiovascular benefit.
Sections du résumé
BACKGROUND
Hyperuricemia and sarcopenia are both strongly linked to an increased risk of atherosclerotic cardiovascular disease (ASCVD), and this study was designed to look into the interactive effects of hyperuricemia on ASCVD risk.
METHODS
This study collected information from patients (N = 2647) who underwent health check-ups at the Health Care Building of Wuhan Union Hospital between January 2019 and December 2020. Skeletal muscle mass was measured using bioelectrical impedance methods. The Asian Working Group on Sarcopenia diagnostic criteria were used to classify patients with sarcopenia. ASCVD risk was calculated using the Framingham Heart Study, and ASCVD risk ≥ 20% was considered high risk ASCVD. IBM SPSS 25.0 and GraphPad prism 8.0 software were used for data analysis and graphing.
RESULTS
The prevalence of hyperuricemia and sarcopenia was 23.57% and 15.34%, respectively. The occurrence of cardiovascular risk factors such as obesity, hypertension, diabetes mellitus, chronic kidney disease, and low HDL-Cemia was significantly higher in subjects with hyperuricemia combined with sarcopenia (OR = 1.734, 3.064, 1.61, 8.77 and 1.691 respectively, p < 0.05); Hyperuricemia and high-risk ASCVD were independently associated (OR = 1.355, 95% CI = 1.000-1.838, p = 0.04). Although there was no significant association between sarcopenia and high-risk ASCVD after controlling for confounders (OR = 1.274, 95% CI = 0.828-1.959, p = 0.271), sarcopenia combined with hyperuricemia significantly increased high-risk ASCVD (OR = 3.229, 95% CI 1.544-6.751, p = 0.002).
CONCLUSION
Hyperuricemia is independently associated with high-risk ASCVD; Sarcopenia and high-risk ASCVD did not show an independent relationship, but there was a synergistic effect of the two on ASCVD risk, which may imply that managing both hyperuricemia and sarcopenia may have a greater cardiovascular benefit.
Identifiants
pubmed: 37370012
doi: 10.1186/s12872-023-03336-2
pii: 10.1186/s12872-023-03336-2
pmc: PMC10294447
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
325Informations de copyright
© 2023. The Author(s).
Références
Contrib Nephrol. 2018;192:88-102
pubmed: 29393133
JAMA. 1991 Dec 4;266(21):3008-11
pubmed: 1820474
Nutrients. 2021 Apr 24;13(5):
pubmed: 33923252
Circ Res. 2016 Jun 24;119(1):159-76
pubmed: 27340274
Hypertension. 2017 Oct;70(4):703-711
pubmed: 28808071
Zhonghua Nei Ke Za Zhi. 2020 Jul 1;59(7):519-527
pubmed: 32594685
J Am Med Dir Assoc. 2020 Mar;21(3):300-307.e2
pubmed: 32033882
Sci Rep. 2017 Aug 1;7(1):7041
pubmed: 28765572
Age Ageing. 2014 Nov;43(6):748-59
pubmed: 25241753
Circulation. 2008 Feb 12;117(6):743-53
pubmed: 18212285
Int J Mol Sci. 2021 Aug 23;22(16):
pubmed: 34445808
J Nutr Health Aging. 2016;20(9):912-917
pubmed: 27791221
Diabetes Obes Metab. 2016 Oct;18(10):962-72
pubmed: 27324560
Neurosci Lett. 2019 Feb 16;694:129-135
pubmed: 30521947
Exp Clin Endocrinol Diabetes. 2021 Jan;129(1):50-55
pubmed: 30541167
N Engl J Med. 2008 Oct 23;359(17):1811-21
pubmed: 18946066
Int J Clin Pract. 2021 Mar;75(3):e13800
pubmed: 33108697
Nutrients. 2021 Dec 16;13(12):
pubmed: 34960057
J Endocrinol. 2016 May;229(2):R67-81
pubmed: 26931135
Eur Heart J. 2021 Mar 1;42(9):896-903
pubmed: 33417682
Arterioscler Thromb Vasc Biol. 2008 Jun;28(6):1186-92
pubmed: 18356554
Int J Cardiol. 2018 Oct 1;268:216-221
pubmed: 29650344
Curr Pharm Des. 2009;15(3):290-303
pubmed: 19149619
J Hepatol. 2016 Apr;64(4):925-32
pubmed: 26639394
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Curr Hypertens Rep. 2017 Sep;19(9):69
pubmed: 28770533
Calcif Tissue Int. 2017 Sep;101(3):229-247
pubmed: 28421264
Clin Chim Acta. 2020 Apr;503:181-189
pubmed: 31794768
Am J Gastroenterol. 2020 Apr;115(4):584-595
pubmed: 32141917
BMC Geriatr. 2022 Feb 12;22(1):121
pubmed: 35151263
Metabolism. 2021 Jun;119:154766
pubmed: 33766485
Clin Appl Thromb Hemost. 2016 Jul;22(5):405-11
pubmed: 25667237
Diabetes. 2011 Jan;60(1):306-14
pubmed: 20978091
Lancet. 2019 Jun 29;393(10191):2636-2646
pubmed: 31171417
J Clin Med. 2020 Jun 28;9(7):
pubmed: 32605201
J Clin Med. 2019 Aug 12;8(8):
pubmed: 31408958
J Clin Lipidol. 2018 May - Jun;12(3):734-740
pubmed: 29523408
Heart Vessels. 2020 Jun;35(6):769-775
pubmed: 31970510
Nutr Metab Cardiovasc Dis. 2020 Feb 10;30(2):300-305
pubmed: 31648885
J Hypertens. 2022 Apr 1;40(4):704-711
pubmed: 34939996
Front Endocrinol (Lausanne). 2022 Mar 10;13:852290
pubmed: 35370951
Biochim Biophys Acta Mol Basis Dis. 2018 Aug;1864(8):2557-2565
pubmed: 29733945
Nat Rev Nephrol. 2016 Dec;12(12):721-737
pubmed: 27748389
Atherosclerosis. 2013 Nov;231(1):61-8
pubmed: 24125412
Clin Res Cardiol. 2021 Jul;110(7):1096-1105
pubmed: 33846840
Aging Clin Exp Res. 2019 Jun;31(6):793-798
pubmed: 31148100
Nutrients. 2020 Jan 14;12(1):
pubmed: 31947528
Int J Endocrinol. 2014;2014:105168
pubmed: 25136362
Hepatology. 2016 Mar;63(3):776-86
pubmed: 26638128
J Am Geriatr Soc. 2013 Mar;61(3):319-26
pubmed: 23496291
J Am Soc Nephrol. 2015 Nov;26(11):2831-8
pubmed: 25788527
Biomed Res Int. 2015;2015:762820
pubmed: 26640795
J Biol Chem. 2017 May 26;292(21):8705-8715
pubmed: 28348082
J Clin Hypertens (Greenwich). 2012 Jun;14(6):346-52
pubmed: 22672087
Sci Rep. 2016 Jan 27;6:19520
pubmed: 26814153
J Hypertens. 2018 Oct;36(10):1953-2041
pubmed: 30234752